Dabigatran: oral prophylaxis for venous thromboembolism

Dabigatran (Pradaxa) is a new orally active antithrombotic agent licensed for VTE prophylaxis following hip and knee replacement. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and adverse effects and Professor Simon Frostick comments on its place in therapy. Copyright © 2008 Wiley Interface Ltd